论文部分内容阅读
目的就CAl5-3、CAl25、CEA在乳腺癌术前化学药物治疗疗效的评估作用进行探讨。方法 2010年1月~2011年12月我院共收治乳腺癌患者48例,采集标本分离血清,对血清中CEA、CAl25、CAl5-3用罗氏cobas e60l试剂和免疫分析仪进行检测。结果本组患者中临床有效42例,无效6例,有效率为87.5%。42例有效组患者,血清CEA、CAl25、CAl5-3在化疗后出现了较为明显的降低,具有统计学意义(P<0.05);而6例无效组患者,血清CEA、CAl25、CAl5-3在化疗后基本无变化。与单项检测相比,任意两项组合与单项相比,没有较为明显的差异,而任意三项组合则与单项检测、任意两项组合相比,具有较为明显的差异。结论在评价肿瘤标志物时,应尽量采用三项联检的方法,有利于提高乳腺癌新辅助化疗疗效。
Objective To evaluate the efficacy of CAl5-3, CA125 and CEA in the preoperative chemotherapy of breast cancer. Methods From January 2010 to December 2011, 48 cases of breast cancer were treated in our hospital. Serum samples were collected for serum CEA, CA125 and CA15-3 using Roche cobas e60l reagent and immunoassay analyzer. Results The clinical efficacy of 42 patients in this group, 6 cases were ineffective, the effective rate was 87.5%. In 42 effective patients, serum CEA, CAl25 and CAl5-3 showed a significant decrease after chemotherapy, with statistical significance (P <0.05); while in 6 invalid patients, serum CEA, CAl25 and CAl5-3 After chemotherapy basically no change. Compared with the single test, any two combinations have no obvious difference compared with the single ones, but any three combinations have obvious differences compared with the single test and any two combinations. Conclusion In the evaluation of tumor markers, should be used as much as possible three joint method, is conducive to improving the efficacy of neoadjuvant chemotherapy for breast cancer.